Rob Davis, Merck CEO
June 17, 2022 11:26 AM EDTUpdated 12:21 PM
Deals
Pharma

Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

Paul Schloesser

Associate Editor

Mer­ck is eval­u­at­ing a po­ten­tial buy­out of em­bat­tled Seat­tle biotech Seagen, ac­cord­ing to a re­port from the Wall Street Jour­nal on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times